Company intelligence / Profile preview

Sun Holdings

Princeton, NJ, USAnlrb.gov ↗

Ownership: Private
Employees: ~19124
Development stage: Commercial

Overview

Sun Pharmaceutical Holdings USA operates as the U.S. holding arm of Sun Pharmaceutical Industries Limited. It manages subsidiaries that develop and commercialize both generic and branded pharmaceuticals across multiple therapeutic areas. The company has recently completed Phase 3 trials for deuruxolitinib in alopecia areata with an NDA filed to FDA; it also markets several approved specialty drugs in dermatology and ophthalmology. Its pipeline includes both small molecules and biologics.

Therapeutic areas: OncologyEndocrinologyPsychiatryDermatologyRheumatologyCardiovascularOphthalmologyNeurology
Modalities: Small moleculeBiologicMonoclonal antibodyPeptidesRecombinant protein
Industry: Biotech

Partnerships

Churchill Pharmaceuticals (“Yonsa”)

Beyond the preview

Go deeper on Sun Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sun Holdings.

Explore the full profile